← Back to Clinical Trials
Recruiting NCT06954194

NCT06954194 Syntactic Intervention for Cantonese-speaking Children With DLD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06954194
Status Recruiting
Phase
Sponsor The Hong Kong Polytechnic University
Condition Developmental Language Disorder
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2024-02-10
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 8 Years
Study Type INTERVENTIONAL
Interventions
Explicit intervention (Shape Coding+syntactic priming)Implicit intervention (syntactic priming only)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2024-02-10 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the efficacy of explicit vs. implicit intervention on subject relative clause production in Cantonese-speaking children with Developmental Language Disorder (DLD). It will also learn about individual difference predictors of intervention outcomes. The main questions it aims to answer are: 1. Will the explicit intervention (Shape Coding+syntactic priming) on relative clause production lead to better outcomes than implicit intervention (syntactic priming only)? 2. Can pre-intervention procedural learning, working memory (WM) capacities, and grammar impairment severity predict the intervention outcomes across children with DLD? 3. Will 10 intervention sessions (500 doses of the target structure) lead to learning progress in children with DLD, even with implicit intervention, and will the progress plateau at some point of the intervention? Researchers will compare the explicit intervention to the implicit intervention to see if the explicit intervention leads to better interventional outcomes. Participants will: * Undergo diagnostic assessments of DLD to confirm their DLD status. * Complete pre-intervention assessments to assess their procedural learning and working memory capacities. * Undergo the intervention phase, which consists of a pretest, 10 intervention sessions, three posttests (after the 1st, 5th and 10th intervention), and a retention test (1 month after the last intervention).

Eligibility Criteria

Inclusion Criteria: * being Cantonese dominant who learned Cantonese as their first language and attending Cantonese-medium primary schools. * having normal IQ and no hearing impairment. * scoring at least -1.25 SD below the mean in any two subtests of the Hong Kong Cantonese Oral Language Assessment Scale (a standardized language assessment tool for Hong Kong Cantonese-speaking children). Exclusion Criteria: * Autism Spectrum Disorder.

Contact & Investigator

Central Contact

Tracy Tang

✉ tracy-wh.tang@polyu.edu.hk

📞 852 34008541

Principal Investigator

Caicai Zhang, PhD

PRINCIPAL INVESTIGATOR

The Hong Kong Polytechnic University

Frequently Asked Questions

Who can join the NCT06954194 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 8 Years, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06954194 currently recruiting?

Yes, NCT06954194 is actively recruiting participants. Contact the research team at tracy-wh.tang@polyu.edu.hk for enrollment information.

Where is the NCT06954194 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT06954194 clinical trial?

NCT06954194 is sponsored by The Hong Kong Polytechnic University. The principal investigator is Caicai Zhang, PhD at The Hong Kong Polytechnic University. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology